<p>You are about to enter the global website of the B. Braun Group. We recommend you visit the website of your local B. Braun organization.</p>

United States - B. Braun Medical Inc.

Global - B. Braun Melsungen AG

<p>Not all products are registered and approved for sale in all countries or regions. Indications of use also may vary by country and region. Please contact your country representative for product availability and information. Product images are for reference only.</p>

Cancel

You have successfully logged out.

Expertise in the ICU

Acute therapies

Extracorporeal blood treatment plays an important role in the management of patients in intensive care settings. Depending on the clinical situation, different therapies may be required to support organ function or address specific pathological processes. A structured approach and the ability to adapt therapies to individual patient needs are essential in this environment.

ICU and acute care relevance

In intensive care and other acute care settings, extracorporeal blood treatment (EBT) is used as part of the clinical management of patients with severe or rapidly changing conditions. These therapies may support kidney function, enable plasma‑based treatments, or be integrated into broader multi‑organ support strategies. EBT is typically embedded in interdisciplinary intensive care units (ICU) workflows and adjusted to the patient’s clinical status.

Therapy Categories

Continuous Renal Replacement Therapy (CRRT) is a continuous form of hemodialysis used in critically ill patients with acute kidney injury. It gently removes waste, corrects electrolytes, and manages fluid balance in hemodynamically unstable patients by purification of blood through a semi‑permeable membrane.

Slow Continuous Ultrafiltration (SCUF) is an extracorporeal therapy designed specifically for fluid removal in patients with volume overload. Using low blood-flow rates and a hemofilter, it removes plasma water with minimal solute clearance. It may be used in patients with diuretic-resistant heart failure or refractory fluid overload, particularly when hemodynamic stability is a concern.

Hemoperfusion (HP) is an extracorporeal blood purification therapy in which anticoagulated whole blood passes through a cartridge containing adsorbent materials to remove toxins, cytokines, or other harmful solutes. It is used to treat selected cases of acute poisoning, severe inflammation, and other critical-care conditions.

Double Filtration Plasmapheresis (DFPP) and Therapeutic Plasma Exchange (TPE) are plasma therapies that remove harmful plasma constituents. DFPP uses two filtration steps to selectively eliminate large pathogenic molecules while returning beneficial proteins. TPE removes plasma entirely and replaces it with donor plasma or albumin to rapidly clear autoantibodies, cytokines, or immune complexes.

Extracorporeal CO₂ Removal (ECCO₂R) is a low‑flow extracorporeal life‑support therapy that removes carbon dioxide from venous blood using a membrane device. It may support patients with hypercapnic respiratory failure or ARDS by facilitating lung-protective ventilation. Compared with ECMO, ECCO₂R is a lower-intensity therapy that provides minimal oxygenation support.